Nifty Pharma Rallies 7% In February, Closer To Its 52-Week High

The Nifty Pharma index has positioned itself as one of the top performers on the Indian stock markets. The index rallied approximately 7% so far this month, outperforming the broad Nifty 50’s 0.56 % gain over the same period. As the index nears its 52-week high of 23,492.55, investors are closely watching whether momentum can be sustained in the face of mixed overall market sentiment and sector-specific dynamics.

So what’s driving this sharp upswing in pharma stocks, and is the index poised for fresh highs?

Why Has The Nifty Pharma Index Outperformed Broader Markets?

The long-only trend in pharmaceutical stocks has been among the most visible sectoral stories in Indian equities this February. The Nifty Pharma index is currently trading near 23,400–23,500, just a whisker below its 52-week peak, with prices having climbed from levels near the low-22,000s earlier in the month.

This roughly 7% advance contrasts sharply with broad market indices; the Nifty 50 has barely registered a meaningful up-move, while key benchmark indices ended largely flat in recent sessions.

Market data shows that the index has been progressively higher across consecutive sessions; a five-session winning streak has lifted the pharma index by nearly 4% before its weekly gains were tallied.

Which Stocks Are Driving The Pharma Surge?

The rally has been broad-based across key constituents of the index, with several individual large-cap pharma names delivering outsized contributions to the sector’s performance:

Laurus Labs has led the charge with gains of around 13% in February, thus signalling strong investor demand for mid-cap pharma players. Moreover, the stocks of Sun Pharmaceutical Industries and Torrent Pharmaceuticals increased by 11%.

Other notable movers include Mankind Pharma, which rallied around 6% in intra-day trade, and several mid-tier constituents such as Zydus Lifesciences, Glenmark Pharmaceuticals, Alkem Laboratories, Aurobindo Pharma and Divis Laboratories, which have posted gains on positive sectoral rotation.

Index weightage data indicates that heavyweights such as Sun Pharma alone account for more than 23% of the Nifty Pharma index, while other names like Divis, Torrent, Dr Reddy’s, Cipla and Lupin together contribute substantially to the sector’s market-cap–weighted returns.

Also Read - Canara Bank Issues 10-Year Tier-II Bonds To Raise ₹5,000 Crore

What Are The Broader Market And Sector Drivers?

Several macro and micro factors contribute to the robust performance of pharma stocks relative to the broader market in February:

Earnings and industry fundamentals: The pharmaceutical sector’s earnings growth for the December quarter (Q3 FY26) was reported at around 12.3% year-on-year, driven largely by strong domestic sales and demand in chronic therapies, which has lent credibility to valuations in a traditionally defensive sector.

Sector rotation amid IT weakness: The key indices like the Nifty IT have experienced pressure, with sharp sell-offs related to AI-related concerns. This has helped insulate the Nifty Pharma index from broader market scepticism.

Export growth and long-term outlook: Separate industry data show that India’s pharmaceutical exports grew by around 9.4% in FY25 to about $30.47 billion, supporting a positive medium-term outlook for companies with global reach.

Sources

Business Standard

Economic Times